Research programme: nano-particle based therapeutics - Topas Therapeutics

Drug Profile

Research programme: nano-particle based therapeutics - Topas Therapeutics

Alternative Names: Nano-particle based peptide therapeutics - Topas Therapeutics

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Topas Therapeutics
  • Class Anti-inflammatories; Immunotherapies; Peptide fragments; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple sclerosis
  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 25 Jan 2018 Topas Therapeutics plans a clinical trial for Autoimmune disorders in 2019
  • 22 Mar 2016 Topas Therapeutics in-licenses Tolerance induction platform technology from the University Medical Center Hamburg-Eppendorf
  • 22 Mar 2016 Early research in Autoimmune disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top